Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0001610717-23-000401 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-15 | 2023-12-13 | CHRS | Reider Paul | Chief Commercial Off | F - Tax | $2.37 | -2,049 | 88.4K | -2% | -$4,856 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | F | D | 2,049 | $2.37 | 88,406 | D | — | — | (F1) Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. (F2) Includes 3,402 shares acquired on May 15, 2023 pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. |